Sheldon L Kaplan1, William J Barson2, Philana Ling Lin3, José R Romero4, John S Bradley5, Tina Q Tan6, Pia S Pannaraj7, Laurence B Givner8, Kristina G Hulten9. 1. Department of Pediatrics, Pediatric Infectious Diseases Section, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas; skaplan@bcm.edu. 2. Department of Pediatrics, Nationwide Children's Hospital and College of Medicine and Public Health, The Ohio State University, Columbus, Ohio. 3. Department of Pediatrics, Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 4. Department of Pediatrics, Arkansas Children's Hospital and University of Arkansas for Medical Sciences, Little Rock, Arkansas. 5. Department of Pediatrics, Rady Children's Hospital-San Diego and University of California, San Diego, San Diego, California. 6. Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago and Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 7. Department of Pediatrics, Children's Hospital Los Angeles and School of Medicine, University of Southern California, Los Angeles, California; and. 8. Department of Pediatrics, Brenner Children's Hospital and Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina. 9. Department of Pediatrics, Pediatric Infectious Diseases Section, Texas Children's Hospital and Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in the United States in 2010. We describe invasive pneumococcal disease (IPD) in children at 8 children's hospitals in the US from 2014 to 2017. METHODS: Children with IPD occurring from 2014 to 2017 were identified from a prospective study. Demographic and clinical data, including results of any immune evaluation along with the number and dates of previous pneumococcal conjugate vaccines administered, were recorded on case report forms. Isolate serotypes were determined in a central laboratory. Pneumococcal conjugate vaccine doses were counted if IPD occurred ≥2 weeks after a dose. RESULTS: PCV13 serotypes accounted for 23.9% (115 out of 482) of IPD isolates from 2014 to 2017. Serotypes 3, 19A, and 19F accounted for 91% of PCV13 serotypes. The most common non-PCV13 serotypes were 35B, 23B, 33F, and 22F. An underlying condition was significantly (P < .0001) more common in children with IPD due to non-PCV13 serotypes (200 out of 367, 54.5%) than for children with PCV13 serotypes (27 out of 115, 23.5%). An immune evaluation was undertaken in 28 children who received ≥2 PCV13 doses before IPD caused by a PCV13 serotype. Only 1 was found to have an immunodeficiency. CONCLUSIONS: PCV13 serotypes (especially serotypes 3, 19A, and 19F) continue to account for nearly a quarter of IPD in US children 4 to 7 years after PCV13 was introduced. Underlying conditions are more common in children with non-PCV13 serotype IPD. Immune evaluations in otherwise healthy children with PCV13 serotype IPD despite receiving ≥2 PCV13 doses did not identify an immunodeficiency.
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed in the United States in 2010. We describe invasive pneumococcal disease (IPD) in children at 8 children's hospitals in the US from 2014 to 2017. METHODS:Children with IPD occurring from 2014 to 2017 were identified from a prospective study. Demographic and clinical data, including results of any immune evaluation along with the number and dates of previous pneumococcal conjugate vaccines administered, were recorded on case report forms. Isolate serotypes were determined in a central laboratory. Pneumococcal conjugate vaccine doses were counted if IPD occurred ≥2 weeks after a dose. RESULTS: PCV13 serotypes accounted for 23.9% (115 out of 482) of IPD isolates from 2014 to 2017. Serotypes 3, 19A, and 19F accounted for 91% of PCV13 serotypes. The most common non-PCV13 serotypes were 35B, 23B, 33F, and 22F. An underlying condition was significantly (P < .0001) more common in children with IPD due to non-PCV13 serotypes (200 out of 367, 54.5%) than for children with PCV13 serotypes (27 out of 115, 23.5%). An immune evaluation was undertaken in 28 children who received ≥2 PCV13 doses before IPD caused by a PCV13 serotype. Only 1 was found to have an immunodeficiency. CONCLUSIONS: PCV13 serotypes (especially serotypes 3, 19A, and 19F) continue to account for nearly a quarter of IPD in US children 4 to 7 years after PCV13 was introduced. Underlying conditions are more common in children with non-PCV13 serotype IPD. Immune evaluations in otherwise healthy children with PCV13 serotype IPD despite receiving ≥2 PCV13 doses did not identify an immunodeficiency.
Authors: Richael O Mills; Mohammed R Abdullah; Samuel A Akwetey; Dorcas C Sappor; Isaac Cole; Michael Baffuor-Asare; Johan A Bolivar; Gustavo Gámez; Mark P G van der Linden; Sven Hammerschmidt Journal: Microorganisms Date: 2020-12-13
Authors: Sweta M Patel; Yazdani B Shaik-Dasthagirisaheb; Morgan Congdon; Rebecca R Young; Mohamed Z Patel; Tiny Mazhani; Sefelani Boiditswe; Tirayaone Leburu; Kwana Lechiile; Tonya Arscott-Mills; Andrew P Steenhoff; Kristen A Feemster; Samir S Shah; Coleen K Cunningham; Stephen I Pelton; Matthew S Kelly Journal: PLoS One Date: 2022-01-05 Impact factor: 3.240
Authors: Luca G Valente; Ngoc Dung Le; Melissa Pitton; Gabriele Chiffi; Denis Grandgirard; Stephan M Jakob; David R Cameron; Grégory Resch; Yok-Ai Que; Stephen L Leib Journal: PLoS One Date: 2022-04-26 Impact factor: 3.752
Authors: Tianyan Hu; Yan Song; Nicolae Done; Qing Liu; Eric M Sarpong; Esteban Lemus-Wirtz; James Signorovitch; Salini Mohanty; Thomas Weiss Journal: BMC Public Health Date: 2022-09-05 Impact factor: 4.135